Literature DB >> 9049837

A possible growth factor role of IL-6 in neuroectodermal tumours.

E Candi1, R A Knight, A Spinedi, P Guerrieri, G Melino.   

Abstract

Preliminary data have shown that IL-6 may act as an autocrine growth factor to control proliferation. We further characterised the role of IL-6 in tumour growth as an autocrine/paracrine growth factor in neuroectodermal tumours. We evaluated the production and secretion of IL-6 by seven human melanoma, five neuroblastoma and one glioblastoma cell lines. Moreover, we determined their IL-6-dependent growth in serum free-medium or under minimal growth-supplement conditions: IL-6 dependent growth was observed in two non-IL-6 producing melanoma and in one neuroblastoma cell lines. In addition, expression of IL-6 mRNA and peptide was increased by retinoic acid. The data support the hypothesis that IL-6 contributes to neuroectodermal tumour growth, even though it shows a less potent effect than other reported growth factor such as IGF-II.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049837     DOI: 10.1023/a:1005706019048

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors.

Authors:  N Sidell; T Taga; T Hirano; T Kishimoto; A Saxon
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

2.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro.

Authors:  F J Burrows; D O Haskard; I R Hart; J F Marshall; S Selkirk; S Poole; P E Thorpe
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  Signals transduced via insulin-like growth factor I receptor (IGF(R)) mediate resistance to retinoic acid-induced cell growth arrest in a human neuroblastoma cell line.

Authors:  K Matsumoto; E Lucarelli; C Minniti; C Gaetano; C J Thiele
Journal:  Cell Death Differ       Date:  1994-07       Impact factor: 15.828

5.  Human melanoma cells transcribe interleukin 1 genes identical to those of monocytes.

Authors:  U Shabon; J L Bennicelli; D P Guerry; H Koprowski; R P Ricciardi
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

6.  Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II.

Authors:  O M El-Badry; J A Romanus; L J Helman; M J Cooper; M M Rechler; M A Israel
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

7.  Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines.

Authors:  M P Colombo; C Maccalli; S Mattei; C Melani; M Radrizzani; G Parmiani
Journal:  Melanoma Res       Date:  1992-09       Impact factor: 3.599

8.  Heterogeneity of cytokine production by human malignant melanoma cells.

Authors:  C A Armstrong; D C Tara; C E Hart; A Köck; T A Luger; J C Ansel
Journal:  Exp Dermatol       Date:  1992-07       Impact factor: 3.960

9.  Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.

Authors:  Y Levy; A Tsapis; J C Brouet
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

10.  Modulation of POMC expression in human neuroectodermal cells.

Authors:  V De Laurenzi; G Melino; R A Knight; A R Pierotti; P Cohen
Journal:  Biochem Biophys Res Commun       Date:  1993-12-30       Impact factor: 3.575

View more
  10 in total

Review 1.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.

Authors:  R E Kast
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Astrocytic alterations in interleukin-6/Soluble interleukin-6 receptor alpha double-transgenic mice.

Authors:  A G Brunello; J Weissenberger; A Kappeler; C Vallan; M Peters; S Rose-John; J Weis
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 4.  Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review.

Authors:  Shahdabul Faraz; Susan Pannullo; Marc Rosenblum; Andrew Smith; A Gabriella Wernicke
Journal:  Ther Adv Med Oncol       Date:  2016-08-18       Impact factor: 8.168

5.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

Authors:  Maria-del-Mar Inda; Rudy Bonavia; Akitake Mukasa; Yoshitaka Narita; Dinah W Y Sah; Scott Vandenberg; Cameron Brennan; Terrance G Johns; Robert Bachoo; Philipp Hadwiger; Pamela Tan; Ronald A Depinho; Webster Cavenee; Frank Furnari
Journal:  Genes Dev       Date:  2010-08-15       Impact factor: 11.361

6.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.

Authors:  Rachel A Egler; Susan M Burlingame; Jed G Nuchtern; Heidi V Russell
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor).

Authors:  Joanne P Lagmay; Wendy B London; Thomas G Gross; Amanda Termuhlen; Nicholas Sullivan; Amy Axel; Bethany Mundy; Mark Ranalli; Jason Canner; Patrick McGrady; Brett Hall
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.

Authors:  Tasnim Ara; Liping Song; Hiroyuki Shimada; Nino Keshelava; Heidi V Russell; Leonid S Metelitsa; Susan G Groshen; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

10.  Cytokine patterns in brain tumour progression.

Authors:  Radu Albulescu; Elena Codrici; Ionela Daniela Popescu; Simona Mihai; Laura Georgiana Necula; Daniel Petrescu; Mihaela Teodoru; Cristiana Pistol Tanase
Journal:  Mediators Inflamm       Date:  2013-06-24       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.